GSK confirms £500 million UK investment, more to follow?
This article was originally published in Scrip
Just one day after the UK budget confirmed that the long awaited "patent box" would slash corporation tax, GlaxoSmithKline has today confirmed it will indeed be investing £500 million in UK manufacturing. But while UK industry appears to believe that the patent box and yesterday's budget make the UK more competitive, they say there is still more to do to guarantee investment.
You may also be interested in...
Recommendations from the Alliance for Regenerative Medicine aim to improve cross-border healthcare to ensure patients can access advanced therapies.
Patient access schemes have helped the Scottish Medicines Consortium recommend rare disease products, including Regeneron/Sanofi’s Libtayo for skin cancer.
In an exclusive interview, senior NICE director Meindert Boysen reveals the best advice he ever received and how companies whose products are under review can improve their chances of success.